Digest Network Come funziona
Network
/
Società
En
Non verificato

Enodia Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaHIV, AIDS e malattie autoimmuniIndustriaSalute

4 comunicati stampa

Guarda tutti i comunicati
13/10/2026
Biotecnologia
Salute
Scienza
Farmaceutica
Mercato del lavoro
Industria
Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules
Fonte
Enodia Therapeutics
Emittente
Business Wire
1.00
0
15/04/2026
Enodia Therapeutics Appoints Dr. Yvonne McGrath as Chief Scientific Officer to Accelerate Upstream Targeted Protein Degradation Platform
Fonte
Enodia Therapeutics
Emittente
Business Wire
1.00
0
08/01/2026
Biotecnologia
Farmaceutica
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Tecnica
Enodia Therapeutics Secures €20.7M to Advance a Small-Molecule Platform for Targeted Protein Degradation Enabled by Proteomics and Machine Learning
Fonte
Enodia Therapeutics
Emittente
Business Wire
1.00
0
26/02/2025
Multimedialità
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Biotecnologia
Salute
Sanità
Oncologia
Industria
Argobio and the Institut Pasteur Launch Enodia Therapeutics: A Biotech Company With a New Approach for Targeted Protein Degradation
Fonte
Enodia Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0